2025 Q4 -tulosraportti
76 päivää sitten
‧48 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 28 | - | - | ||
| 50 | - | - | ||
| 862 | - | - | ||
| 194 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 19.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenYet another irrelevant update. We know that BLC is better. They have tested, analyzed, and told us this for months already. Rather, come with something new, something that actually means something, like what's happening with the royalty dispute, and how realistic are the sales estimates? But instead, we get yet another study, this time published in The Journal of Medical Economics – which "shows" that blue light cystoscopy (BLC) is cost-effective compared to Narrow Band Imaging (NBI) over the patient's lifetime. SHOCKING!! It's starting to look more like repetition than new information. Perhaps it's time to update the market on the questions investors are actually waiting for answers to.·4 t sittenTrying to clear my own thoughts and put the matter to rest. The study largely confirms something the market already knows: BLC (with Hexvix/Cysview) is both clinically superior and cost-effective compared to NBI over time. This is positive, but in itself not really new information. What is more important is what this actually means commercially. This type of health economic analysis naturally strengthens the argument for the use of BLC, especially towards health authorities and potentially for reimbursement processes. At the same time, it is important to distinguish between evidence and actual implementation. The actual cost of adopting BLC, i.e., investment in scope/equipment, training, and organization, largely lies with the hospitals and clinics, not with PHO. As I understand it, PHO does not sell or own the BLC-scope itself, but relies on third-party suppliers for the equipment. This means that volume growth in PHO's business only materializes through increased use of the drug per procedure once hospitals have actually invested in and implemented the technology. Thus, the bottleneck is still not primarily clinical evidence, but rather the investment pace at hospitals, reimbursement systems, and the speed of actual implementation in practice. What makes me a bit more questioning, therefore, is the pattern in the communication. We regularly receive updates on studies, analyses, seminars, and “strengthened evidence”. At the same time, Hexvix/Cysview is already approved, and its clinical effect has been well documented over a long period. This is also not a message that contains new contracts, new market shares, or concrete reimbursement decisions. The question I am left with is therefore quite simple. How much meaning and impact do these types of messages actually have now, in isolation, beyond confirming an already well-established narrative?
·29.4.I think the author's tune will change when Q1 comes with a profit of 80mill+
·29.4.But if we disregard a somewhat tasteless high salary for management, and a total lack of results (e.g. measured as EBITDA or cashflow) it's not going so badly. The share price, for example, is absolutely on par with what it was in the summer of 2002 That it should have been around 115,- solely adjusted for inflation, and thus no excess return, is not much to dwell on. So much else exciting is happening here;-))
·29.4. · MuokattuHehe…I sense a bit of Irony here…😊 But it suddenly picks up speed. Probably an announcement about an agreement with Asieris in the near future, and then we get some good quarterly figures, if not in Q1 then in Q2, then it shoots up.- ·29.4.Huh, no trading the first 30min? Something going on?
·29.4. · MuokattuKari Eian Krogstad CEO at Medistim cost a total of 4,866,446 kroner in 2025, the entire 8-person management cost 16,890,166 kroner. Total revenue in 2025 was 442,562,000, increased from 354,048,000 in 2024. Every year they also pay the dividend, I don't understand why Daniel Schneider cost over 11 million in 2025 and 6 managers at PHO should cost over 2 times more than 8 managers at Medistim. The problem is not the management but the board, it is they who decide salaries - ·25.4.Most of the uncertainties now appear to be resolved, and further negative surprises are expected to a limited extent. The dispute related to milestone payments is expected to be resolved at a later date, but regardless of the outcome, both Asieris and Photocure are expected to deliver solid earnings in the current year. In the short term, the share price will see a rebound, with the potential to move towards 75 kroner already next Monday. Furthermore, a gradual positive development is expected leading up to the presentation of the 1Q26 results, with the possibility that the price breaks the 80-kroner level prior to the report. After a longer period that has required significant patience from investors, the stage may now be set for a more visible return. Congratulations to all Photocure shareholders who have been through good and less good days.·28.4. · MuokattuIt will take time to get significant payments from the Chinese. In the meantime, PHO must deliver good figures. Soon it will be May 7th, and mostly the share price falls after a presentation. The result will be embellished with USD 6,5 mil from the Chinese.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
76 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenYet another irrelevant update. We know that BLC is better. They have tested, analyzed, and told us this for months already. Rather, come with something new, something that actually means something, like what's happening with the royalty dispute, and how realistic are the sales estimates? But instead, we get yet another study, this time published in The Journal of Medical Economics – which "shows" that blue light cystoscopy (BLC) is cost-effective compared to Narrow Band Imaging (NBI) over the patient's lifetime. SHOCKING!! It's starting to look more like repetition than new information. Perhaps it's time to update the market on the questions investors are actually waiting for answers to.·4 t sittenTrying to clear my own thoughts and put the matter to rest. The study largely confirms something the market already knows: BLC (with Hexvix/Cysview) is both clinically superior and cost-effective compared to NBI over time. This is positive, but in itself not really new information. What is more important is what this actually means commercially. This type of health economic analysis naturally strengthens the argument for the use of BLC, especially towards health authorities and potentially for reimbursement processes. At the same time, it is important to distinguish between evidence and actual implementation. The actual cost of adopting BLC, i.e., investment in scope/equipment, training, and organization, largely lies with the hospitals and clinics, not with PHO. As I understand it, PHO does not sell or own the BLC-scope itself, but relies on third-party suppliers for the equipment. This means that volume growth in PHO's business only materializes through increased use of the drug per procedure once hospitals have actually invested in and implemented the technology. Thus, the bottleneck is still not primarily clinical evidence, but rather the investment pace at hospitals, reimbursement systems, and the speed of actual implementation in practice. What makes me a bit more questioning, therefore, is the pattern in the communication. We regularly receive updates on studies, analyses, seminars, and “strengthened evidence”. At the same time, Hexvix/Cysview is already approved, and its clinical effect has been well documented over a long period. This is also not a message that contains new contracts, new market shares, or concrete reimbursement decisions. The question I am left with is therefore quite simple. How much meaning and impact do these types of messages actually have now, in isolation, beyond confirming an already well-established narrative?
- ·29.4.I think the author's tune will change when Q1 comes with a profit of 80mill+
- ·29.4.But if we disregard a somewhat tasteless high salary for management, and a total lack of results (e.g. measured as EBITDA or cashflow) it's not going so badly. The share price, for example, is absolutely on par with what it was in the summer of 2002 That it should have been around 115,- solely adjusted for inflation, and thus no excess return, is not much to dwell on. So much else exciting is happening here;-))·29.4. · MuokattuHehe…I sense a bit of Irony here…😊 But it suddenly picks up speed. Probably an announcement about an agreement with Asieris in the near future, and then we get some good quarterly figures, if not in Q1 then in Q2, then it shoots up.
- ·29.4.Huh, no trading the first 30min? Something going on?·29.4. · MuokattuKari Eian Krogstad CEO at Medistim cost a total of 4,866,446 kroner in 2025, the entire 8-person management cost 16,890,166 kroner. Total revenue in 2025 was 442,562,000, increased from 354,048,000 in 2024. Every year they also pay the dividend, I don't understand why Daniel Schneider cost over 11 million in 2025 and 6 managers at PHO should cost over 2 times more than 8 managers at Medistim. The problem is not the management but the board, it is they who decide salaries
- ·25.4.Most of the uncertainties now appear to be resolved, and further negative surprises are expected to a limited extent. The dispute related to milestone payments is expected to be resolved at a later date, but regardless of the outcome, both Asieris and Photocure are expected to deliver solid earnings in the current year. In the short term, the share price will see a rebound, with the potential to move towards 75 kroner already next Monday. Furthermore, a gradual positive development is expected leading up to the presentation of the 1Q26 results, with the possibility that the price breaks the 80-kroner level prior to the report. After a longer period that has required significant patience from investors, the stage may now be set for a more visible return. Congratulations to all Photocure shareholders who have been through good and less good days.·28.4. · MuokattuIt will take time to get significant payments from the Chinese. In the meantime, PHO must deliver good figures. Soon it will be May 7th, and mostly the share price falls after a presentation. The result will be embellished with USD 6,5 mil from the Chinese.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 28 | - | - | ||
| 50 | - | - | ||
| 862 | - | - | ||
| 194 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 19.2.2025 |
2025 Q4 -tulosraportti
76 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 19.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenYet another irrelevant update. We know that BLC is better. They have tested, analyzed, and told us this for months already. Rather, come with something new, something that actually means something, like what's happening with the royalty dispute, and how realistic are the sales estimates? But instead, we get yet another study, this time published in The Journal of Medical Economics – which "shows" that blue light cystoscopy (BLC) is cost-effective compared to Narrow Band Imaging (NBI) over the patient's lifetime. SHOCKING!! It's starting to look more like repetition than new information. Perhaps it's time to update the market on the questions investors are actually waiting for answers to.·4 t sittenTrying to clear my own thoughts and put the matter to rest. The study largely confirms something the market already knows: BLC (with Hexvix/Cysview) is both clinically superior and cost-effective compared to NBI over time. This is positive, but in itself not really new information. What is more important is what this actually means commercially. This type of health economic analysis naturally strengthens the argument for the use of BLC, especially towards health authorities and potentially for reimbursement processes. At the same time, it is important to distinguish between evidence and actual implementation. The actual cost of adopting BLC, i.e., investment in scope/equipment, training, and organization, largely lies with the hospitals and clinics, not with PHO. As I understand it, PHO does not sell or own the BLC-scope itself, but relies on third-party suppliers for the equipment. This means that volume growth in PHO's business only materializes through increased use of the drug per procedure once hospitals have actually invested in and implemented the technology. Thus, the bottleneck is still not primarily clinical evidence, but rather the investment pace at hospitals, reimbursement systems, and the speed of actual implementation in practice. What makes me a bit more questioning, therefore, is the pattern in the communication. We regularly receive updates on studies, analyses, seminars, and “strengthened evidence”. At the same time, Hexvix/Cysview is already approved, and its clinical effect has been well documented over a long period. This is also not a message that contains new contracts, new market shares, or concrete reimbursement decisions. The question I am left with is therefore quite simple. How much meaning and impact do these types of messages actually have now, in isolation, beyond confirming an already well-established narrative?
- ·29.4.I think the author's tune will change when Q1 comes with a profit of 80mill+
- ·29.4.But if we disregard a somewhat tasteless high salary for management, and a total lack of results (e.g. measured as EBITDA or cashflow) it's not going so badly. The share price, for example, is absolutely on par with what it was in the summer of 2002 That it should have been around 115,- solely adjusted for inflation, and thus no excess return, is not much to dwell on. So much else exciting is happening here;-))·29.4. · MuokattuHehe…I sense a bit of Irony here…😊 But it suddenly picks up speed. Probably an announcement about an agreement with Asieris in the near future, and then we get some good quarterly figures, if not in Q1 then in Q2, then it shoots up.
- ·29.4.Huh, no trading the first 30min? Something going on?·29.4. · MuokattuKari Eian Krogstad CEO at Medistim cost a total of 4,866,446 kroner in 2025, the entire 8-person management cost 16,890,166 kroner. Total revenue in 2025 was 442,562,000, increased from 354,048,000 in 2024. Every year they also pay the dividend, I don't understand why Daniel Schneider cost over 11 million in 2025 and 6 managers at PHO should cost over 2 times more than 8 managers at Medistim. The problem is not the management but the board, it is they who decide salaries
- ·25.4.Most of the uncertainties now appear to be resolved, and further negative surprises are expected to a limited extent. The dispute related to milestone payments is expected to be resolved at a later date, but regardless of the outcome, both Asieris and Photocure are expected to deliver solid earnings in the current year. In the short term, the share price will see a rebound, with the potential to move towards 75 kroner already next Monday. Furthermore, a gradual positive development is expected leading up to the presentation of the 1Q26 results, with the possibility that the price breaks the 80-kroner level prior to the report. After a longer period that has required significant patience from investors, the stage may now be set for a more visible return. Congratulations to all Photocure shareholders who have been through good and less good days.·28.4. · MuokattuIt will take time to get significant payments from the Chinese. In the meantime, PHO must deliver good figures. Soon it will be May 7th, and mostly the share price falls after a presentation. The result will be embellished with USD 6,5 mil from the Chinese.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 100 | - | - | ||
| 28 | - | - | ||
| 50 | - | - | ||
| 862 | - | - | ||
| 194 | - | - |
Välittäjätilasto
Dataa ei löytynyt